Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country

作者
Kunjahari Medhi,Vinod Raina,Lalit Kumar,Atul Sharma,Sameer Bakhshi,Ritu Gupta,Rajive Kumar
出处
期刊:Leukemia & Lymphoma [Taylor & Francis]
卷期号:51 (10): 1850-1854 被引量:10
标识
DOI:10.3109/10428194.2010.507416
摘要

Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is a standard of care for chronic myeloid leukemia (CML). There are few publications on responses of patients with CML from the Indian subcontinent. This study analyzed the response rate, progression-free survival (PFS), overall survival (OS), and toxicities in patients with CML given imatinib. Analysis included patients with CML who received imatinib under the GIPAP program at our institution from January 2002 to December 2008. Standard criteria for hematological and cytogenetic responses were used. There were 400 patients, with a median follow-up of 47 months. One hundred and seventy received prior non-imatinib therapy and 230 patients received imatinib upfront. Ninety-five percent of patients achieved complete hematological response. The cumulative best rate of major cytogenetic response was 72%, with 53% complete cytogenetic response and 19% partial cytogenetic response. The estimated PFS and OS at median follow-up for the whole group was 76% and 94%, respectively. Differences in PFS and OS in prior non-imatinib and upfront imatinib groups were not statistically significant. However, better PFS and OS were seen in the upfront imatinib group. Imatinib was well tolerated in our study.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被帅气的小鸭子采纳,获得20
刚刚
刚刚
刚刚
Zoey完成签到,获得积分10
刚刚
1秒前
rongliy完成签到,获得积分10
1秒前
chole发布了新的文献求助10
2秒前
yi发布了新的文献求助10
2秒前
2秒前
2秒前
1717发布了新的文献求助10
3秒前
脱羰甲酸发布了新的文献求助10
3秒前
方青松发布了新的文献求助10
3秒前
雪落发布了新的文献求助10
3秒前
Ava的应助被乐观的大树采纳,获得10
3秒前
3秒前
5秒前
Hello的应助被steplight采纳,获得10
5秒前
方方土发布了新的文献求助10
5秒前
蓝天的应助被steplight采纳,获得10
5秒前
万能图书馆的应助被steplight采纳,获得10
5秒前
星辰大海的应助被steplight采纳,获得10
5秒前
小二郎的应助被steplight采纳,获得10
5秒前
蓝天的应助被steplight采纳,获得10
5秒前
所所的应助被steplight采纳,获得10
5秒前
细心鲂完成签到,获得积分20
5秒前
赘婿的应助被steplight采纳,获得10
6秒前
思源的应助被steplight采纳,获得10
6秒前
科研通AI65的应助被陈陌与采纳,获得10
6秒前
肥龙宝宝发布了新的文献求助10
7秒前
dit发布了新的文献求助10
8秒前
嘻嘻哈哈的应助被lifarshad采纳,获得10
8秒前
加点辣椒面吧完成签到,获得积分10
8秒前
斯文败类的应助被DW采纳,获得10
10秒前
11秒前
夜绿完成签到,获得积分10
11秒前
12秒前
Adzuki0812完成签到,获得积分10
12秒前
斯文败类的应助被肥龙宝宝采纳,获得10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188353
求助须知:如何正确求助?哪些是违规求助? 9576169
关于积分的说明 21845860
捐赠科研通 7786410
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482235